Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BCD-180 in Healthy Volunteers
NCT05407779Phase 1Completed
- Sponsor
- BIOCAD
- Start
- Jan 2021
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of seniprutug in ankylosing spondylitis (AS) (9 cohorts), sponsored by BIOCAD. Primary endpoint: Proportion of subjects with adverse reactions at Day 361. Started Jan 2021; status: completed.
02
Drugs
seniprutug
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT05407779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05407779.